Here in Birmingham we are striving to secure a position as a strategic centre, driving major improvements in patient outcomes by building upon our strengths in stratified medicine and immuno-oncology, and leveraging our integrated biomedical campus and large population.
Birmingham Experimental Cancer Medicine Centre (ECMC) is one of eighteen adult centres across the UK and is led by Professor Gary Middleton. Jointly funded by Cancer Research UK and the National Institute for Health Research (NIHR), the ECMC Network seeks to accelerate the translation of discovery science into the clinic by promoting rational development and application of novel therapies, providing clinical networks for their evaluation, and supplying linked patient data and samples for future research. The current award period ends in 2022.
The Birmingham ECMC is managed under the umbrella of Birmingham Health Partners, which unites the University of Birmingham with key local clinical partners. Top-level oversight is provided by the Cancer Strategy Board, which has representation from all key partners. Decisions are taken by the ECMC Management Group, which comprises key cancer research stakeholders from across the West Midlands, including the University, University Hospitals Birmingham and the West Midlands, Oxford and Wessex Genomic Laboratory Hub. There is close alignment with the Cancer Research UK Birmingham Centre management, with reciprocal involvement of ECMC and Centre Directors and theme leads in respective management structures.
We understand the unique insights that patients and the public can bring to research and are committed to increasing the levels of meaningful involvement to enable collaborative development of research via our growing Involvement and Engagement in Cancer Research at Birmingham group. More information can be found on our working with people affected by cancer webpage.